JP3518547B2 - 同種移植および調和異種移植の拒否反応の阻害 - Google Patents

同種移植および調和異種移植の拒否反応の阻害

Info

Publication number
JP3518547B2
JP3518547B2 JP50651691A JP50651691A JP3518547B2 JP 3518547 B2 JP3518547 B2 JP 3518547B2 JP 50651691 A JP50651691 A JP 50651691A JP 50651691 A JP50651691 A JP 50651691A JP 3518547 B2 JP3518547 B2 JP 3518547B2
Authority
JP
Japan
Prior art keywords
cyclosporin
rejection
cobra venom
xenografts
survival
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50651691A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05507266A (ja
Inventor
ホワイト，デビッド，ジェームス，グラハム
ファン デン ジョアン ベアーズ ボガード
Original Assignee
イミュトラン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュトラン リミテッド filed Critical イミュトラン リミテッド
Publication of JPH05507266A publication Critical patent/JPH05507266A/ja
Application granted granted Critical
Publication of JP3518547B2 publication Critical patent/JP3518547B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50651691A 1990-04-09 1991-04-04 同種移植および調和異種移植の拒否反応の阻害 Expired - Fee Related JP3518547B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909007971A GB9007971D0 (en) 1990-04-09 1990-04-09 Pharmaceutical formulations
GB9007971.6 1990-04-09
PCT/GB1991/000522 WO1991015221A1 (en) 1990-04-09 1991-04-04 Inhibition of allograft and concordant xenograft rejection

Publications (2)

Publication Number Publication Date
JPH05507266A JPH05507266A (ja) 1993-10-21
JP3518547B2 true JP3518547B2 (ja) 2004-04-12

Family

ID=10674123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50651691A Expired - Fee Related JP3518547B2 (ja) 1990-04-09 1991-04-04 同種移植および調和異種移植の拒否反応の阻害

Country Status (22)

Country Link
EP (1) EP0527762B1 (enExample)
JP (1) JP3518547B2 (enExample)
CN (1) CN1040178C (enExample)
AT (1) ATE141167T1 (enExample)
AU (1) AU7555591A (enExample)
CZ (1) CZ283119B6 (enExample)
DE (1) DE69121401T2 (enExample)
DK (1) DK0527762T3 (enExample)
ES (1) ES2090325T3 (enExample)
GB (1) GB9007971D0 (enExample)
GR (1) GR3021642T3 (enExample)
HK (1) HK48597A (enExample)
IE (1) IE911153A1 (enExample)
IL (1) IL97788A (enExample)
IN (1) IN173149B (enExample)
MY (1) MY106158A (enExample)
NZ (1) NZ237739A (enExample)
PT (1) PT97277B (enExample)
SG (1) SG47465A1 (enExample)
SK (1) SK279949B6 (enExample)
WO (1) WO1991015221A1 (enExample)
ZA (1) ZA912467B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030379A2 (en) * 1999-10-27 2001-05-03 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
JP2004509171A (ja) 2000-09-29 2004-03-25 ゾーン、　ロバート　ズィー． 炎症及び免疫反応の治療方法及びその組成物
NZ551308A (en) * 2004-05-14 2009-06-26 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
US9447176B2 (en) * 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｔｏｘｉｃｏｎ，１９８０，Ｖｏｌ．１８，ｐｐ．８７〜９６

Also Published As

Publication number Publication date
ES2090325T3 (es) 1996-10-16
SK279949B6 (sk) 1999-06-11
CZ283119B6 (cs) 1998-01-14
ATE141167T1 (de) 1996-08-15
DE69121401T2 (de) 1996-12-12
JPH05507266A (ja) 1993-10-21
DK0527762T3 (da) 1996-09-02
GR3021642T3 (en) 1997-02-28
DE69121401D1 (de) 1996-09-19
IL97788A0 (en) 1992-06-21
EP0527762A1 (en) 1993-02-24
MY106158A (en) 1995-03-31
PT97277B (pt) 1998-08-31
SG47465A1 (en) 1998-04-17
AU7555591A (en) 1991-10-30
IE911153A1 (en) 1991-10-09
CN1056240A (zh) 1991-11-20
IL97788A (en) 1998-02-08
ZA912467B (en) 1992-12-30
IN173149B (enExample) 1994-02-19
NZ237739A (en) 1993-09-27
PT97277A (pt) 1992-01-31
GB9007971D0 (en) 1990-06-06
EP0527762B1 (en) 1996-08-14
HK48597A (en) 1997-04-25
CN1040178C (zh) 1998-10-14
CS9100988A2 (en) 1991-12-17
WO1991015221A1 (en) 1991-10-17

Similar Documents

Publication Publication Date Title
CRAMER et al. Cardiac transplantation in the rat: II. Alteration of the severity of donor graft arteriosclerosis by modulation of the host immune response
Hiestand et al. Comparison of the pharmacological profiles of cyclosporine,(Nva2)-cyclosporine and (Val2) dihydro-cyclosporine
Kahan Cyclosporine: A powerful addition to the immunosuppressive armamentarium
HK1222342A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
RU2014837C1 (ru) Средство для лечения панкреатита и предупреждения отторжения трансплантата поджелудочной железы и способ предупреждения отторжения трансплантата поджелудочной железы
US8435520B2 (en) Combinations of immunosuppressive agents for the treatment or prevention of graft rejections
Okuno et al. SQ 14, 225 attenuates the vascular response to norepinephrine in the rat mesenteric arteries
EP0527762B1 (en) Inhibition of allograft and concordant xenograft rejection
US20010018051A1 (en) Inhibition of allograft and concordant xenograft rejection
Anderson et al. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation
Neild et al. Severe systemic vascular necrosis in cyclosporin-treated rabbits with acute serum sickness
US5736136A (en) Immunoglobulin infusion in xenotransplantation
JPS6272621A (ja) コレラ毒素類を活性成分とする免疫抑制剤
JPH09506115A (ja) 細胞毒性薬の副作用を軽減するためのトランスフェリン組成物
Black et al. Cyclosporine-induced long-term allograft survival and its potential in posttrauma tissue replacement
Novitzky, D., Cooper, DKC & Wicomb A successful method of administering cyclosporin A to the chacma baboon
Takiff et al. Low-dose cyclosporine maintenance therapy after immunosuppressive induction in a rat cardiac transplant model
Ludwin et al. Prolonged allograft survival resulting from donor pretreatment with phytohemagglutinin-P
Cofer et al. Effects of pre-and postengraftment donor-specific transfusions and cyclosporine on the enhancement of experimental allograft survival
de Bruin et al. The effect of pretransplant donor-specific blood transfusions on various segments of small bowel grafts
Kahn et al. Use of verapamil with conventional immunosuppression after porcine renal transplantation
Maxwell et al. Cyclosporine
Braun et al. Immunosuppression
Pruitt et al. Soluble Complement Receptor and Hyperacute Rejection

Legal Events

Date Code Title Description
A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040120

LAPS Cancellation because of no payment of annual fees